NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe

Contributed by: GlobeNewswire

Tags

Healthcare

More Like This

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy

NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025